Abstract
A critical issue in drug development is developing effective, noninvasive delivery routes to the central nervous system (CNS). Major depressive disorder (MDD) is an illness associated with significant morbidity. Even with multiple antidepressant trials, 10–15% of patients continue to experience persistent depressive symptoms. We previously developed an interfering peptide that has antidepressant-like effects in rats when injected directly into the brain. To be clinically viable, it must demonstrate efficacy via a noninvasive administration route. We report here that the interfering peptide designed to disrupt the interaction between the D1 and D2 dopamine receptors can be delivered to relevant brain areas using the Pressurized Olfactory Device (POD), a novel intranasal delivery system developed by Impel NeuroPharma. We validate this delivery method by demonstrating that, at doses ⩾1.67 nmol/g, the D1–D2 interfering peptide has a significant antidepressant-like effect comparable to that of imipramine in the forced swimming test (FST), a common test for antidepressant efficacy. The antidepressant-like effect of the interfering peptide can be detected for 2 h after intranasal administration. Furthermore, we show that the interfering peptide disrupts the D1–D2 interaction and it can be detected in the prefrontal cortex after intranasal administration. This study provides strong preclinical support for intranasal administration of the D1–D2 interfering peptide as a new treatment option for patients suffering from MDD.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Autry AE, Monteggia LM (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 64: 238–258.
Baker H, Spencer RF (1986). Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 63: 461–473.
Beaulieu JM, Gainetdinov RR (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63: 182–217.
Belmaker RH, Agam G (2008). Major depressive disorder. N Engl J Med 358: 55–68.
Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey IW (1998). Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1: 35–44.
Cuijpers P (2011). The patient perspective in research on major depression. BMC Psychiatry 11: 89.
De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N et al (2005). Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 102: 3811–3816.
Dhuria SV, Hanson LR, Frey WH 2nd (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99: 1654–1673.
Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003). Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60: 804–815.
Fletcher L, Kohli S, Sprague SM, Scranton RA, Lipton SA, Parra A et al (2009). Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J Neurosurg 111: 164–170.
Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J et al (2008). Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131 (Pt 12): 3311–3334.
Free RB, Hazelwood LA, Cabrera DM, Spalding HN, Namkung Y, Rankin ML et al (2007). D1 and D2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. J Biol Chem 282: 21285–21300.
Hasbi A, O'Dowd BF, George SR (2011). Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance. Mol Brain 4: 26.
Hoekman JD, Ho RJ (2011a). Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech 12: 534–543.
Hoekman JD, Ho RJ (2011b). Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth Analg 113: 641–651.
Hopp TP, Prickett KS, Price VL, Libby RT, March CJ, Cerretti DP et al (1988). A short polypeptide marker sequence useful for recombinant protein identification and purification. Nat Biotechnol 6: 1204–1210.
Jansson B, Bjork E (2002). Visualization of in vivo olfactory uptake and transfer using fluorescein dextran. J Drug Target 10: 379–386.
Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R (2005). Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136: 29–37.
Lee FJ, Liu F (2004). Direct interactions between NMDA and D1 receptors: a tale of tails. Biochem Soc Trans 32 (Pt 6): 1032–1036.
Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB (2000). Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 403: 274–280.
Liu XF, Fawcett JR, Thorne RG, Frey WH 2nd (2001). Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 308: 91–94.
Lucki I (1997). The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8: 523–532.
Maggio R, Aloisi G, Silvano E, Rossi M, Millan MJ (2009). Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. Parkinsonism Relat Disord 15 (Suppl 4): S2–S7.
Mann JJ (2005). The medical management of depression. N Engl J Med 353: 1819–1834.
Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA (2009). Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci 29: 6734–6751.
Missale C, Fiorentini C, Collo G, Spano P (2010). The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. J Recept Signal Transduct Res 30: 347–354.
Mojtabai R (2009). Unmet need for treatment of major depression in the United States. Psychiatr Serv 60: 297–305.
Nijboer CH, Heijnen CJ, Groenendaal F, May MJ, van Bel F, Kavelaars A (2008). Strong neuroprotection by inhibition of NF-kappaB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines. Stroke 39: 2129–2137.
O'Dowd BF, Nguyen T, Ji X, George SR (2013). D5 dopamine receptor carboxyl tail involved in D5-D2 heteromer formation. Biochem Biophys Res Commun 431: 586–589.
Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y (2008). Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol 11: 1047–1061.
Papakostas GI (2009). Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 70 (Suppl 6): 16–25.
Pei L, Lee FJ, Moszczynska A, Vukusic B, Liu F (2004). Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J Neurosci 24: 1149–1158.
Pei L, Li S, Wang M, Diwan M, Anisman H, Fletcher PJ et al (2010). Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med 16: 1393–1395.
Perreault ML, Hasbi A, Alijaniaram M, Fan T, Varghese G, Fletcher PJ et al (2010). The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem 285: 36625–36634.
Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379–391.
Porsolt RD, Le Pichon M, Jalfre M (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730–732.
Renner DB, Svitak AL, Gallus NJ, Ericson ME, Frey WH 2nd, Hanson LR (2012). Intranasal delivery of insulin via the olfactory nerve pathway. J Pharm Pharmacol 64: 1709–1714.
Ridray S, Griffon N, Mignon V, Souil E, Carboni S, Diaz J et al (1998). Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. Eur J Neurosci 10: 1676–1686.
Ross TM, Zuckermann RN, Reinhard C, Frey WH 2nd (2008). Intranasal administration delivers peptoids to the rat central nervous system. Neurosci Lett 439: 30–33.
Schwartz JC, Diaz J, Bordet R, Griffon N, Perachon S, Pilon C et al (1998). Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence. Brain Res Brain Res Rev 26: 236–242.
Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569–1572.
Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T (2012). Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metabol 97: 366–376.
So CH, Verma V, Alijaniaram M, Cheng R, Rashid AJ, O'Dowd BF et al (2009). Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol Pharmacol 75: 843–854.
Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF et al (2007). Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 164: 739–752.
Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127: 481–496.
Tucker JC, File SE (1986). The effects of tricyclic and ‘atypical’ antidepressants on spontaneous locomotor activity in rodents. Neurosci Biobehav Rev 10: 115–121.
van Beljouw I, Verhaak P, Prins M, Cuijpers P, Penninx B, Bensing J (2010). Reasons and determinants for not receiving treatment for common mental disorders. Psychiatr Serv 61: 250–257.
Wong AH, Liu F (2012). Uncoupling the dopamine D1-D2 receptor complex: a novel target for antidepressant treatment. Clin Pharmacol Ther 91: 298–302.
Wu H, Hu K, Jiang X (2008). From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv 5: 1159–1168.
Yang D, Sun YY, Lin X, Baumann JM, Dunn RS, Lindquist DM et al (2013). Intranasal delivery of cell-penetrating anti-NF-kappaB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury. Exp Neurol 247: 447–455.
Acknowledgements
We thank members in Dr Liu’s lab (P Su, F Lee, S Li, D Zhai, and T Lu) for their technical support. We thank J Hokeman and Impel NeuroPharma for their advice regarding the use of the POD device. We thank Dr P Fletcher for his help with experimental design. V Brown conducted all experiments and co-wrote the manuscript. F Liu conceived of all experiments and co-wrote the manuscript. This work is supported by the Canadian Institutes for Health Research (CIHR; to FL).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brown, V., Liu, F. Intranasal Delivery of a Peptide with Antidepressant-Like Effect. Neuropsychopharmacol 39, 2131–2141 (2014). https://doi.org/10.1038/npp.2014.61
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2014.61
This article is cited by
-
Development of a peptide targeting dopamine transporter to improve ADHD-like deficits
Molecular Brain (2018)
-
Intranasal delivery of a Fas-blocking peptide attenuates Fas-mediated apoptosis in brain ischemia
Scientific Reports (2018)
